Literature DB >> 6749700

Antihypertensive effect of nicardipine hydrochloride in essential hypertension.

T Takabatake, H Ohta, Y Yamamoto, M Maekawa, S Arai, N Hattori, G Nomura.   

Abstract

The antihypertensive effect of a new calcium antagonist, nicardipine hydrochloride (YC-93), was studied in 47 mild to moderate essential hypertensives. YC-93 (30-60 mg/day) was administered orally alone for 8 weeks (Group I, 31 patients) or in combination with diuretics, beta blockers, or both (Group II, 16 patients). Blood pressure was reduced from 173.6 +/- 2.2/103.5 +/- 1.7 to 139.7 +/- 2.0/87.2 +/- 1.1 mmHg in Group I and from 172.9 +/- 3.9/108.9 +/- 2.9 to 140.5 +/- 2.3/89.5 +/- 2.5 mm Hg in Group II. Pulse rate was not altered in Group I but increased transiently in Group II. The side effects seen in seven patients were mostly related to the vasodilatation and were generally transient and mild. These results indicate that YC-93 is an effective antihypertensive drug for the treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749700

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  11 in total

1.  Effect of nicardipine on haemodynamic response to stress in hypertension.

Authors:  T Takabatake; Y Yamamoto; S Nakamura; N Hashimoto; S Satoh; Y Yamada; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers.

Authors:  B A van Schaik; R J Hene; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension.

Authors:  J Levenson; A C Simon; J Bouthier; B C Maarek; M E Safar
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension.

Authors:  J P Cox; J Ryan; E O'Brien; K O'Malley
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension.

Authors:  T Takabatake; Y Yamamoto; S Nakamura; N Hashimoto; S Satoh; Y Yamada; H Ohta; N Hattori
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Nicardipine in the treatment of essential hypertension controlled 6-month-study comparing nicardipine with propranolol at rest and during exercise.

Authors:  A Danielsson; P Bjerle; B Ek; L Steen; O Suhr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients.

Authors:  T Takabatake; H Ohta; T Sasaki; S Satoh; K Ohta; T Ise; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Antihypertensive and renal effects of nicardipine.

Authors:  B A van Schaik; A E van Nistelrooy; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

Review 10.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.